Table I.
Association between Cbx2 expression and patient clinicopathological features.
| Cbx2 expression | ||||
|---|---|---|---|---|
| Parameter | n | Low, n (%) | High, n (%) | P-value |
| Age, years | 0.441 | |||
| <50 | 249 | 119 (47.8) | 130 (52.2) | |
| ≥50 | 206 | 91 (44.2) | 115 (55.8) | |
| Tumor size, cm | <0.001 | |||
| <2 | 101 | 65 (64.4) | 36 (35.6) | |
| ≥2 | 353 | 144 (40.8) | 209 (59.2) | |
| Pathological stage | 0.286 | |||
| I | 40 | 23 (57.5) | 17 (42.5) | |
| II | 121 | 56 (46.3) | 65 (53.7) | |
| III | 285 | 126 (44.2) | 159 (55.8) | |
| LNM | 0.008 | |||
| Negative | 210 | 111 (52.9) | 99 (47.1) | |
| Positive | 245 | 99 (40.4) | 146 (59.6) | |
| TNM stage | <0.001 | |||
| I | 91 | 75 (82.4) | 16 (17.6) | |
| II | 225 | 131 (58.2) | 94 (41.8) | |
| III | 139 | 4 (2.9) | 135 (97.1) | |
| Ki-67, % | 0.080 | |||
| <10 | 147 | 77 (52.4) | 70 (47.6) | |
| ≥10 | 305 | 133 (43.6) | 172 (56.4) | |
| HER-2 status | 0.048 | |||
| Negative | 363 | 176 (48.5) | 187 (51.5) | |
| Positive | 92 | 34 (37.0) | 58 (63.0) | |
| ER status | 0.162 | |||
| Negative | 242 | 104 (43.0) | 138 (57.0) | |
| Positive | 212 | 105 (49.5) | 107 (50.5) | |
| PR status | 0.174 | |||
| Negative | 180 | 76 (42.2) | 104 (57.8) | |
| Positive | 275 | 134 (48.7) | 141 (51.3) | |
| p53 status | 0.717 | |||
| Negative | 79 | 35 (44.3) | 44 (55.7) | |
| Positive | 376 | 175 (46.5) | 201 (53.5) | |
| Subtype | 0.388 | |||
| HER-2 | 92 | 37(40.2) | 55 (59.8) | |
| Luminal A | 85 | 44 (51.8) | 41 (48.2) | |
| Luminal B | 234 | 111 (47.4) | 123 (52.6) | |
| Triple negative | 44 | 18 (40.9) | 26 (59.1) | |
Cbx2, chromobox2; LNM, lymph node metastasis; TNM, tumor node metastasis; HER-2, human epidermal growth factor-2; ER, estrogen receptor; PR, progesterone receptor; p53, tumor protein 53.